Description
PRINCIPIO ACTIVO: TRIMEBUTINA
KADCYLA® 160 mg es un medicamento de uso intravenoso que contiene Trastuzumab Emtansina (T-DM1)
2 cm Contenido: Adicionadas con extractos naturales de manzanilla
Uso bajo protocolos clínicos y normativas sanitarias vigentes
CASODEX® 50 mg | Bicalutamida | 28 Tabletas
CENTRUM BALANCE 60 TAB IBRUTINIB PRINCIPIO ACTIVO: TRIMEBUTINAPRINCIPIO ACTIVO: VITAMINAS Y MINERALES
Exchange/Return Notes
- We offer a 30-day return/exchange service after receiving.
- Final sale items are not eligible for returns or exchanges.
- To process your return/exchange, please contact us at [email protected]
- Please click here for more details>>> Return & Exchange Policy
You may also like
recommand products
